BRAF and squamous cell carcinoma: It has be reported that the development of cutaneous squamous cell carcinomas during BRAF inhibitor therapy is caused by activation of the MAPK pathway in keratinocytes with preexisting RAS mutations commonly found in chronically sun damaged skin.